206 related articles for article (PubMed ID: 29896907)
1. Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.
Saleeb RM; Farag M; Lichner Z; Brimo F; Bartlett J; Bjarnason G; Finelli A; Rontondo F; Downes MR; Yousef GM
Mol Oncol; 2018 Oct; 12(10):1673-1688. PubMed ID: 29896907
[TBL] [Abstract][Full Text] [Related]
2. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
[TBL] [Abstract][Full Text] [Related]
3. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
4. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
5. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
6. Identification of prognostic and therapeutic biomarkers in type 2 papillary renal cell carcinoma.
Wang Y; Tian X; Zhu SX; Xu WH; Anwaier A; Su JQ; Gan HL; Qu YY; Zhao JY; Zhang HL; Ye DW
World J Surg Oncol; 2023 Mar; 21(1):98. PubMed ID: 36927438
[TBL] [Abstract][Full Text] [Related]
7. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.
Dong Y; Manley BJ; Becerra MF; Redzematovic A; Casuscelli J; Tennenbaum DM; Reznik E; Han S; Benfante N; Chen YB; Arcila ME; Aras O; Voss MH; Feldman DR; Motzer RJ; Fabbri N; Healey JH; Boland PJ; Chawla M; Durack JC; Lee CH; Coleman JA; Russo P; Hakimi AA; Cheng EH; Hsieh JJ
Eur Urol Focus; 2017 Dec; 3(6):590-598. PubMed ID: 28753786
[TBL] [Abstract][Full Text] [Related]
8. Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases.
Marsaud A; Dadone B; Ambrosetti D; Baudoin C; Chamorey E; Rouleau E; Lefol C; Roussel JF; Fabas T; Cristofari G; Carpentier X; Michiels JF; Amiel J; Pedeutour F
Genes Chromosomes Cancer; 2015 Jun; 54(6):369-82. PubMed ID: 25820192
[TBL] [Abstract][Full Text] [Related]
9. ABCC2 expression in papillary renal cell carcinoma provides better prognostic stratification than WHO/ISUP nucleolar grade.
Saleeb RM; Brimo F; Gao Y; Boulos C; Kim SS; Al Bashir S; Husain A; Rotondo F; Beharry V; Bjarnason GA; Krizova A; Trpkov K; Yousef GM
Hum Pathol; 2022 Feb; 120():57-70. PubMed ID: 34958810
[TBL] [Abstract][Full Text] [Related]
10. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
11. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
Tang Q; Pan D; Xu C; Chen L
J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of gene expression and integrin-associated signaling pathways in papillary renal cell carcinoma subtypes.
Zhang K; Lee HM; Wei GH; Manninen A
Oncotarget; 2016 Dec; 7(51):84178-84189. PubMed ID: 27705936
[TBL] [Abstract][Full Text] [Related]
13. Circular RNA Eps15-homology domain-containing protein 2 induce resistance of renal cell carcinoma to sunitinib via microRNA-4731-5p/ABCF2 axis.
Li W; Li G; Cao L
Bioengineered; 2022 Apr; 13(4):9729-9740. PubMed ID: 35412955
[TBL] [Abstract][Full Text] [Related]
14. The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
Zou Y; Wang J; Leng X; Huang J; Xue W; Zhang J; Huang Y
Oncotarget; 2017 Mar; 8(13):20825-20833. PubMed ID: 28212559
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.
Adelaiye-Ogala R; Damayanti NP; Orillion AR; Arisa S; Chintala S; Titus MA; Kao C; Pili R
Cancer Res; 2018 Jun; 78(11):2886-2896. PubMed ID: 29572225
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant.
Tsuruda M; Yoshino H; Okamura S; Kuroshima K; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
PLoS One; 2020; 15(5):e0232545. PubMed ID: 32379831
[TBL] [Abstract][Full Text] [Related]
17. Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification.
Lu Z; Pan Y; Wang S; Wu J; Miao C; Wang Z
Eur J Med Res; 2024 Apr; 29(1):236. PubMed ID: 38622715
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies and the treatment of non-clear cell renal cell carcinoma.
Bellmunt J; Dutcher J
Ann Oncol; 2013 Jul; 24(7):1730-1740. PubMed ID: 23625974
[TBL] [Abstract][Full Text] [Related]
19. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
20. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
